Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Researchers develop new scoring method to predict bleeding risk after stroke

A new scoring method may help predict who is at high risk of serious bleeding after a stroke, according to a study published in the August 2, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.

2 Aug 2017

Low-risk atrial fibrillation patients fare better without antithrombotic therapy, study finds

Findings from a large, community-based study show that antithrombotic therapy doesn't decrease low-risk atrial fibrillation patients' risk of suffering a stroke within five years. In fact, researchers found that low-risk patients fared better without any antithrombotic therapy.

17 Mar 2017

Genetic testing at UMMC helps doctors identify effective medication for heart stent patients

The University of Maryland Medical Center is now offering a simple genetic test to patients who receive heart stents to determine whether they have a genetic deficiency that affects how they respond to a common drug to prevent blood clots.

12 Jan 2017

Euro Heart Index 2016: France ranks 1st in heart care

Heart care in France ranks 1st among 30 measured countries, says the Euro Heart Index 2016 (EHI), published today in Brussels. The Index compares heart care in 30 European countries, with France the champion, closely followed by Norway and Sweden.

8 Dec 2016

New guidelines recommend use of antiplatelet therapy and exercise program for treatment of PAD

New guidelines for the treatment of peripheral artery disease (PAD), include recommendations on the use of antiplatelet therapy to reduce the risk of blood clots and statin drugs to lower cholesterol and advise PAD patients to participate in a structured exercise program.

13 Nov 2016

NCDR provides data to study appropriate use of oral anticoagulant therapy

The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.

30 Sep 2016

Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers reported here.

29 Aug 2016

New study to examine genomics of anti-platelet therapy after coronary interventions

Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.

29 Jul 2016

'Novel' analysis addresses antiplatelet benefits in real-world CHD patients

Researchers demonstrate a means of gauging the effects of drugs tested in randomised trials in real-world patients.

28 Jun 2016

CYP2C19 gene variants undermine clopidogrel stroke prevention

The first look at CYP2C19 mutations in the context of a randomised controlled trial has confirmed suspicions that they affect the efficacy of clopidogrel in patients with acute stroke.

24 Jun 2016

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications.

22 May 2016

Younger women more likely to experience one-year adverse cardiovascular events after PCI

Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. The PROMETHEUS study found that outcomes for both men and women post-PCI are dependent on their baseline risk factors, not their sex.

9 May 2016

UPMC uses simple gene test to personalize medications for patients undergoing heart catheterization

Patients who go to UPMC Presbyterian for heart catheterization and who receive a stent to treat clogged arteries are now being screened with a simple blood test to determine if they have a gene variant that makes them less likely to respond to a blood-thinning medication commonly prescribed after the procedure.

11 Feb 2016

New study finds efficacy of novel intravenous blood thinner in women

Percutaneous coronary intervention (PCI) is a staple of modern day medicine in which cardiologists place a stent in a blood vessel around the heart in order to restore blood flow in people with heart disease. Blood thinners allow for the procedure to be completed with a reduced risk of certain complications such as clots.

18 Jan 2016

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research.

7 Dec 2015

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Ticagrelor administered in the ambulance reduces ischaemic events 24 hours after primary percutaneous coronary intervention (PCI), according to findings from the ATLANTIC-H24 study presented for the first time today at ESC Congress.

1 Sep 2015

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen Pharmaceuticals, Inc., and its development partner, Bayer HealthCare, today announced results from PMSS (Post-Marketing Safety Surveillance) and XANTUS (XARELTO for Prevention of Stroke in Patients with Atrial Fibrillation), their landmark real-world studies evaluating the safety of XARELTO in people with non-valvular atrial fibrillation (NVAF).

1 Sep 2015

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Fatal bleeding is rare with extended dual antiplatelet therapy, according to a secondary analysis of the DAPT Study presented for the first time today at ESC Congress. Bleeding-related mortality accounted for a minority of deaths in patients treated with dual antiplatelet therapy beyond one year.

1 Sep 2015

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel-based dual antiplatelet therapy is associated with increased major bleeding after stent implantation for high-risk patients with stable coronary artery disease, according to a secondary analysis of the BASKET-PROVE II trial presented at ESC Congress for the first time today.

1 Sep 2015

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

For the first time, ESC Guidelines published today give the highest degree of recommendation for the radial approach over the femoral one for coronary angiography and percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS).

29 Aug 2015

Clopidogrel News and Research

Researchers develop new scoring method to predict bleeding risk after stroke

Low-risk atrial fibrillation patients fare better without antithrombotic therapy, study finds

Genetic testing at UMMC helps doctors identify effective medication for heart stent patients

Euro Heart Index 2016: France ranks 1st in heart care

New guidelines recommend use of antiplatelet therapy and exercise program for treatment of PAD

NCDR provides data to study appropriate use of oral anticoagulant therapy

Study shows non-inferiority of short-term dual antiplatelet therapy in patients with DES placement

New study to examine genomics of anti-platelet therapy after coronary interventions

'Novel' analysis addresses antiplatelet benefits in real-world CHD patients

CYP2C19 gene variants undermine clopidogrel stroke prevention

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Younger women more likely to experience one-year adverse cardiovascular events after PCI

UPMC uses simple gene test to personalize medications for patients undergoing heart catheterization

New study finds efficacy of novel intravenous blood thinner in women

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

Preclinical research using 1 Tesla desktop MRI

Understanding the rise in NTM infections

Counteracting premature aging

Latest News